“GSK’s $2.5 billion restructuring over the next three years will include global job cuts, the company announced in a July 29 media call. CEO Luke Miels declined to say how many employees the U.K. pharma will let go, saying he wanted his team to discuss the changes with staff first and would provide an update once the plans are implemented. He framed the effort as a reallocation toward new medicines.
GSK intends to use part of the expected savings to keep funding its late-stage portfolio and pipeline. Some will also go toward improving margins and profitability ahead of the 2028 U.S. patent expiry for its HIV medicine dolutegravir.”